Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)

TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial

This study compares two surgical techniques used during one-anastomosis gastric bypass (OAGB) surgery for patients with severe obesity. During this operation, surgeons create a bypass of part of the small intestine, and the length of this bypassed segment (called the biliopancreatic limb) affects both weight loss and the risk of nutritional side effects. In this trial, one group of patients has the limb length calculated individually based on the measured total length of their small intestine (TSBL-based method), while the other group receives a limb length based on standard body mass index (BMI) categories (BMI-based method). The study compares weight loss outcomes, improvement of obesity-related health problems, and complication rates between the two approaches over 12 months after surgery. The trial is being conducted at a single center in Almaty, Kazakhstan, and plans to enroll 100 patients total; this record reflects an interim analysis based on the first 75 patients enrolled.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.

In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.

The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.

Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.

Studietype

Ingrijpend

Inschrijving (Geschat)

100

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Almaty, Kazachstan
        • Werving
        • JSC "National Scientific Center of Surgery named after A.N. Syzganov"
        • Contact:
        • Hoofdonderzoeker:
          • Adil Shokebaev

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Age between 18 and 65 years
  • BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
  • Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
  • Eligibility for primary one-anastomosis gastric bypass (OAGB)
  • Provision of written informed consent

Exclusion Criteria:

  • BMI below the defined thresholds
  • Severe decompensated cardiac, pulmonary, hepatic, or renal disease
  • Acute inflammatory conditions
  • Active gastric or duodenal ulcer
  • Psychiatric disorders or substance abuse
  • Pregnancy or breastfeeding
  • Active malignancy
  • Severe intra-abdominal adhesions due to prior surgery
  • Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
Actieve vergelijker: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9, 180 cm for BMI 40-49.9, 200 cm for BMI ≥50.
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Excess Weight Loss (%EWL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m². Assessed longitudinally over time using linear mixed models.
Baseline, 3 months, 6 months, and 12 months post-surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Total Weight Loss (%TWL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
TWL assessed as percentage of total body weight loss relative to baseline weight. Assessed longitudinally over time using linear mixed models.
Baseline, 3 months, 6 months, and 12 months post-surgery
BMI Change
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
Change in body mass index (BMI, kg/m²) from baseline over time.
Baseline, 3 months, 6 months, and 12 months post-surgery
BMI Loss (BMIL)
Tijdsspanne: Baseline, 3 months, 6 months, and 12 months post-surgery
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
Baseline, 3 months, 6 months, and 12 months post-surgery
Improvement in Obesity-Related Comorbidities
Tijdsspanne: 12 months post-surgery
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
12 months post-surgery
Postoperative Complications
Tijdsspanne: 12 months post-surgery
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
12 months post-surgery

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 oktober 2023

Primaire voltooiing (Geschat)

1 november 2027

Studie voltooiing (Geschat)

1 november 2027

Studieregistratiedata

Eerst ingediend

27 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

27 augustus 2026

Eerst geplaatst (Werkelijk)

1 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 september 2026

Laatste update ingediend die voldeed aan QC-criteria

27 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • TSBL-BMI-OAGB

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Individual participant data underlying the results reported in this article, after deidentification, may be shared with researchers upon reasonable request.

IPD-tijdsbestek voor delen

Data will be available beginning 3 months after article publication, with no defined end date, for researchers who provide a methodologically sound proposal.

IPD-toegangscriteria voor delen

Data will be available to researchers who provide a methodologically sound proposal, upon reasonable request to the corresponding author (Nurbol Orynbassar, nurbolorynbassar@gmail.com).

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .